30 Technology- EMA Approval to launch a Phase 1/2a trial in patients with Non-Cystic Fibrosis Bronchiectasis

London, UK, 23 APRIL 2024

30 Technology is thrilled to announce that the European Medicines Agency (EMA) has given approval for our Phase 1/2a trial designed to evaluate the safety, tolerability, and efficacy of nebulised Nitric Oxide Formulations in Non-Cystic Fibrosis Bronchiectasis (NCFB) patients with Pseudomonas Aeruginosa (Pa) or other potentially pathogenic micro-organisms (PPMs) – the NOPA trial.

The trial will take place at four specialist early phase centres in Bulgaria, Romania and Poland and we are targeting August 2024 for the first patient screened. Regulatory submissions are ongoing in other territories, and it is anticipated the study will be enrolled across a total of 6 sites globally.

Stay tuned for further updates as we progress through our research journey to enhance respiratory care.

30 TECHNOLOGY is developing nitric oxide-generating technologies for a range of health care applications